Trevi Therapeutics Q3 2023 net loss $7.7M; initiates Phase 2a RIVER trial for Haduvio in RCC

Trevi Therapeutics, Inc.

2023-Q3 EPS reported -$0.21

Net loss $7.7M in Q3 2023 vs $8.3M in Q3 2022; cash, equivalents $88.9M.
Initiated Phase 2a RIVER trial of Haduvio in refractory chronic cough; topline data expected H2 2024.
Plan to initiate Phase 2b dose-ranging trial for chronic cough in IPF in Q4 2023; Phase 1b trial in Q1 2024.
Open-label extension of PRISM trial in prurigo nodularis showed sustained itch reduction and safety over 52 weeks.
R&D expenses $6.3M, G&A $2.7M; other income $1.3M due to higher interest income.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Trevi Therapeutics, Inc. reported quarter ended September 30, 2023 results: net income net loss of $7.7 million.

Period: quarter ended September 30, 2023
Net income: net loss of $7.7 million
Result: reported results

Exact text from the filing

For the third quarter of 2023, the Company reported a net loss of $7.7 million

View on SEC.gov

Browse all earnings releases →

Trevi Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-062031

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.